TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25287853

Group type: EXPERIMENTAL
Intervention: Pharmacist-based, patient-centered medication review prior to discharge from hospital
Number of subjects: 1626

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 1626

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1626
Study: 22797934

Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard dose clopidogrel
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: VASP-PRI
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: LTA
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MEA
Number of subjects: 82
Study: 20627913

Group type: EXPERIMENTAL
Intervention: 4 months rifampin (4RIF)
Number of subjects: 847

Group type: COMPARATOR
Intervention: 9 months isoniazid (9INH)
Number of subjects: 847
Study: 17430214

Group type: EXPERIMENTAL
Intervention: Bone marrow stem cell therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 15610952

Group type: EXPERIMENTAL
Intervention: pegylated IFN‐alfa (PEG‐IFN‐alfa) 6 microg/kg/week subcutaneously for 8 weeks, followed by 3 microg/kg/week for a total of 5 years
Number of subjects: 17

Group type: COMPARATOR
Intervention: non-treated controls
Number of subjects: 17
Study: 12182803

Group type: EXPERIMENTAL
Intervention: Active exploration of a virtual environment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Passive observation of the virtual environment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Virtual training group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Real training group
Number of subjects: 75

Group type: COMPARATOR
Intervention: No training group
Number of subjects: 75
Study: 9492968

Group type: EXPERIMENTAL
Intervention: Image source entry (forms entered using screen display of faxed forms)
Number of subjects: 1122

Group type: COMPARATOR
Intervention: Double paper source entry (forms entered twice using paper forms)
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Double image source entry (forms entered three times using image source)
Number of subjects: 1122
Study: 12879525

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study: 2392791

Group type: EXPERIMENTAL
Intervention: System 22 Mizer with 50 mg pentamidine (3 ml fill)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: System 22 Mizer with 50 mg pentamidine (6 ml fill)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Respirgard II with 50 mg pentamidine (3 ml fill)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Respirgard II with 50 mg pentamidine (6 ml fill)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: System 22 Mizer with 150 mg pentamidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Respirgard II with 150 mg pentamidine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: System 22 Mizer with increased volume of fill (from 3 to 6 ml)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Respirgard II with increased volume of fill (from 3 to 6 ml)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: System 22 Mizer
Number of subjects: 9

Group type: COMPARATOR
Intervention: Respirgard II
Number of subjects: 9
Study: 1271225

Group type: EXPERIMENTAL
Intervention: Control condition (subjects could determine frequency and duration of visits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predict condition (subjects informed of visit schedule but had no control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random condition (subjects visited on a random schedule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline comparison group (not visited)
Number of subjects: 0
Study: 31099216

Group type: EXPERIMENTAL
Intervention: Floating needle therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 72
Study: 26076014

Group type: EXPERIMENTAL
Intervention: IN0 (before the start of the session at the inlet blood line filled with rinsing solution)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: IN5 (5 min after the start at the inlet line filled with blood)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: OUT0 (before the start of the session at the outlet blood line)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anti-Xa levels below 0.3 IU/mL at the end of the session
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anti-Xa above 0.3 IU/mL at the end of the session
Number of subjects: 13
Study: 23482444

Group type: EXPERIMENTAL
Intervention: Acupuncture with manual and low-frequency electrical stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (meetings with a physical therapist twice a week for 10-13 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 21441444

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol/kg/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Blocking endogenous GLP-1 receptor action
Number of subjects: 24
Study: 19656148

Group type: EXPERIMENTAL
Intervention: Double balloon catheter
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Single balloon catheter
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: PGE(2) gel (2 mg)
Number of subjects: 330
Study: 17275744

Group type: EXPERIMENTAL
Intervention: Active impedance threshold device (impedance 7 cmH2O)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham impedance threshold device (no inspiratory impedance)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Active impedance threshold device
Number of subjects: 22
Study: 16197748

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 5.6% sodium hexametaphosphate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Negative control chewing gum
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium hexametaphosphate gum
Number of subjects: 11
Study: 11730653

Group type: EXPERIMENTAL
Intervention: Vitrectomy surgical group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (fellow eyes)
Number of subjects: 74
Study: 9389919

Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP 1.0 mCi/kg
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP 0.5 mCi/kg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 114
Study: 7525682

Group type: EXPERIMENTAL
Intervention: Inerpan (amino acid copolymer membrane)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Comfeel (hydrocolloid dressing)
Number of subjects: 168
Study: 2448862

Group type: EXPERIMENTAL
Intervention: Irrigation of the maxillary sinus (antroscopy and sinuscopy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No irrigation of the maxillary sinus (control group)
Number of subjects: 80
Study: 29032698

Group type: EXPERIMENTAL
Intervention: Imagery groups (Imagery 1 and Imagery 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 28959813

Group type: EXPERIMENTAL
Intervention: 8 varieties of cooked lentils (low GI values ranging from 10 to 23)
Number of subjects: 10
Study: 25701170

Group type: EXPERIMENTAL
Intervention: Orteronel plus prednisone
Number of subjects: 1560

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 1560
Study: 23697398

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20614859

Group type: EXPERIMENTAL
Intervention: Ondansetron (Ond) 24 mg QD
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluoxetine (Fl) 5 mg QD + Ondansetron (Ond) 12 mg QD
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluoxetine (Fl) 10 mg QD + Ondansetron (Ond) 24 mg QD
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 18787327

Group type: EXPERIMENTAL
Intervention: Auricular electroacupuncture (EA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Autogenic training (AT)
Number of subjects: 44
Study: 16669846

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 7
Study: 12797494

Group type: EXPERIMENTAL
Intervention: salmeterol (50 microg b.i.d.)
Number of subjects: 45

Group type: COMPARATOR
Intervention: fluticasone (100 microg b.i.d.)
Number of subjects: 45
Study: 11347856

Group type: EXPERIMENTAL
Intervention: lacidipine (4‐6 mg o.d.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ) (25‐50 mg o.d.)
Number of subjects: 41

Group type: COMPARATOR
Intervention: lacidipine and HCTZ
Number of subjects: 41
Study: 8626951

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase 0.8 million U (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase 1.6 million U (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase 3.2 million U (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not receiving urokinase)
Number of subjects: 60
Study: 1377074

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin therapy (2 x 10(6) kallikrein inhibitor units intravenous bolus after induction of anaesthesia followed by continuous infusion of 0.5 x 10(6) kallikrein inhibitor units/h until the end of the operation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no aprotinin therapy)
Number of subjects: 20
Study: 6706301

Group type: EXPERIMENTAL
Intervention: 200 mg per day of i.v. SAMe
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 800 mg per day of i.v. SAMe
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no SAMe treatment)
Number of subjects: 18
Study: 31113362

Group type: EXPERIMENTAL
Intervention: Stratified therapy based on mechanistic drivers and biomarkers of AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prediction models developed for AF recurrence and AF-related outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Harmonised analysis of baseline and outcome data from 12 studies
Number of subjects: 0
Study: 30061059

Group type: EXPERIMENTAL
Intervention: Radiation-absorbing surgical drapes
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard surgical draping
Number of subjects: 62
Study: 27629780

Group type: EXPERIMENTAL
Intervention: Psychosocial competency training (PCT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 24438500

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (2 mSv)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Standard-dose computed tomography (8 mSv)
Number of subjects: 3000
Study: 22935561

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (HBV vaccination)
Number of subjects: 156
Study: 19442378

Group type: EXPERIMENTAL
Intervention: Full vocal exercise protocol (FE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Partial vocal exercise protocol (PE)
Number of subjects: 40
Study: 17303766

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (4 individual, weekly sessions)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Usual stroke care
Number of subjects: 411
Study: 15675575

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGF receptor tyrosine kinase inhibitors (gefitinib and erlotinib)
Number of subjects: 0
Study: 15457776

Group type: EXPERIMENTAL
Intervention: Rigid instrumentation (SCS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic instrumentation (TWINFLEX)
Number of subjects: 30
Study: 10422996

Group type: EXPERIMENTAL
Intervention: Pharmacist participation on medical rounds in the ICU
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control unit (no pharmacist participation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pharmacist recommendations related to drug ordering
Number of subjects: 75
Study: 8785381

Group type: EXPERIMENTAL
Intervention: Teasing protocol (sensory exposure to food) in humans
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fasting in humans
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-intensity teasing in dogs
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fasting in dogs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-intensity teasing in dogs
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intragastric food protocol in dogs
Number of subjects: 6
Study: 2206036

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 8245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245
Study: 7399797

Group type: EXPERIMENTAL
Intervention: Topical extract of Peganum harmala
Number of subjects: 0
Study: 30507039

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastroenteric anastomosis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Billroth II gastroenteric anastomosis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall postoperative morbidity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Relaparotomy rate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Duration of hospital stay
Number of subjects: 80
Study: 26544563

Group type: EXPERIMENTAL
Intervention: femtosecond laser-assisted LASIK (femto-LASIK)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: epipolis LASIK (epi-LASIK)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: small incision lenticule extraction (SMILE)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Comparison of SMILE, femto-LASIK, and epi-LASIK
Number of subjects: 303
Study: 23415311

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 600 mg
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study: 21324043

Group type: EXPERIMENTAL
Intervention: Winograd surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sleeve method
Number of subjects: 100
Study: 19142107

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 17535232

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate and miconazole
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clobetasol propionate and placebo
Number of subjects: 35
Study: 14764030

Group type: EXPERIMENTAL
Intervention: Hydrosonography
Number of subjects: 197

Group type: COMPARATOR
Intervention: Transvaginal sonography
Number of subjects: 197
Study: 11754119

Group type: EXPERIMENTAL
Intervention: Nimesulide drop formulation (50 mg x ml(‐1), Medley S/A Indústria Farmacêutica, Brazil)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard nimesulide drop formulation (Nisulid, 50 mg x ml(‐1), Astra Médica, Brazil)
Number of subjects: 24
Study: 9532346

Group type: EXPERIMENTAL
Intervention: Isolated transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 18
Study: 8033369

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (n = 38)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Post-menopausal women with loss greater than 3.5%/2 years
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Elderly osteopenic women (aged 68-72 years)
Number of subjects: 45
Study: 2699786

Group type: EXPERIMENTAL
Intervention: Ultrasound Doppler device (group II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time ultrasonograph (group III)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anatomical landmarks (group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasonographic aid (used in groups I and II for unsuccessful punctures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound methods (group II and III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound methods (group II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echocamera (compared with Doppler ultrasound)
Number of subjects: 0
Study: 792665

Group type: EXPERIMENTAL
Intervention: Encephabol (pyritinol, pyrithioxine) administered orally, parenterally, and combined
Number of subjects: 317
Study: 31018742

Group type: EXPERIMENTAL
Intervention: AS‐OCT imaging
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Slit lamp examination
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Scheimpflug photography
Number of subjects: 50
Study: 27393704

Group type: EXPERIMENTAL
Intervention: Holy Qur'an recitation (experimental group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study: 25546031

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 578

Group type: COMPARATOR
Intervention: Fingolimod
Number of subjects: 578
Study: 23459334

Group type: EXPERIMENTAL
Intervention: Rupatadine (RUP)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Desloratadine (DES)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 356
Study: 20952100

Group type: EXPERIMENTAL
Intervention: Antithrombin treatment (unfractionated heparin, low-molecular-weight heparin, or bivalirudin)
Number of subjects: 2632
Study: 19243723

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 33
Study: 16696845

Group type: EXPERIMENTAL
Intervention: Typical exerciser
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Active living target
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Excessive exerciser
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Non-exerciser
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control target
Number of subjects: 272
Study: 12631051

Group type: EXPERIMENTAL
Intervention: High SBP group (SBP ≥ 140 mmHg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal SBP group (SBP < 140 mmHg)
Number of subjects: 40
Study: 10671927

Group type: EXPERIMENTAL
Intervention: Current hypertension
Number of subjects: 5356

Group type: EXPERIMENTAL
Intervention: Use of antihypertensive medication
Number of subjects: 5356

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 5356

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5356

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 5356

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 5356
Study: 9062439

Group type: EXPERIMENTAL
Intervention: Breast cancer questionnaire (BS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gynaecological cancer questionnaire (GS)
Number of subjects: 0
Study: 8140382

Group type: EXPERIMENTAL
Intervention: Topical vasoconstrictor pre-treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vasoconstrictor pre-treatment (control)
Number of subjects: 0
Study: 4030197

Group type: EXPERIMENTAL
Intervention: PPA 37.5 mg (therapeutic dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30159620

Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis (DBT)
Number of subjects: 14274

Group type: COMPARATOR
Intervention: Digital mammography (DM)
Number of subjects: 14274
Study: 30235903

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 1353

Group type: COMPARATOR
Intervention: Gain-framed messages
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Participants with high personal involvement
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Participants concerned about their health condition
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Participants who suffered a food safety incident
Number of subjects: 1353
Study: 25777061

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (2 mA, 15 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cathodal tsDCS (2 mA, 15 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tsDCS (2 mA, 15 min)
Number of subjects: 10
Study: 23478173

Group type: EXPERIMENTAL
Intervention: Insulin Sensitization (IS)
Number of subjects: 1917

Group type: COMPARATOR
Intervention: Insulin Provision (IP)
Number of subjects: 1917
Study: 22909579

Group type: EXPERIMENTAL
Intervention: Parental behavioral nutrition education to change to reduced-fat dairy foods
Number of subjects: 145

Group type: COMPARATOR
Intervention: Reduce screen time (comparison control)
Number of subjects: 145
Study: 20373130

Group type: EXPERIMENTAL
Intervention: Early abciximab administration before transfer to cathlab (group EA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Late abciximab administration during PPCI (group LA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Selective abciximab administration during PPCI (group SA)
Number of subjects: 73
Study: 18508946

Group type: EXPERIMENTAL
Intervention: Tonsillectomy plus steroid pulse therapy (group C)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Steroid pulse monotherapy (group M)
Number of subjects: 55
Study: 12370222

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients (n=13)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RTX-CSA (n=13)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RTX-FK (n=13)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RTX-Phi (n=6)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy volunteers (CON, n=15)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RTX-NE (n=16)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients before and after RTX (n=4)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RTX patients before and after nephrectomy (n=6)
Number of subjects: 66
Study: 9839851

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate (DH)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 1002
Study: 7848489

Group type: EXPERIMENTAL
Intervention: Preventive GAPS Approach
Number of subjects: 200

Group type: COMPARATOR
Intervention: Existing routines
Number of subjects: 200